Connecticut Innovations
VC Fund
Rocky Hill, United States
Connecticut Innovations is a VC fund in Rocky Hill focused on Health Care and Biotechnology. guidance and introductions to valuable partners, Connecticut innovations enable promising businesses to thrive.
- Total investments:
- 309
- Last investment:
- Lead investor:
- 29%
- Fund size:
- $50M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Connecticut Innovations invests in
Stages Connecticut Innovations invests in
Countries Connecticut Innovations invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
| See all 14 contacts → | |||
Round size
- Seed
- $150k–$5.3M
- Series A
- $1.8M–$25M
- Series B
- $1.8M–$75M
Investment Focus
Industry
- Health Care 73 (24%)
- Biotechnology 49 (16%)
- Software 43 (14%)
- Medical 32 (10%)
- Therapeutics 20 (6%)
Stage
- Seed 75 (24%)
- Series A 62 (20%)
- Series B 31 (10%)
- Venture - Series Unknown 28 (9%)
- Funding Round 22 (7%)
Country
- United States 189 (61%)
- Israel 8 (3%)
- Canada 4 (1%)
- India 3 (1%)
- Belgium 1 (0%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Alison Malloy
Managing Director, Investments
|
Managing Director, Investments | Total investments: 3 | Find email | |
Matthew D. Storeygard
Managing Director, Venture Capital Investments
|
Managing Director, Venture Capital Investments | Total investments: 12 | Find email | |
| CEO | Total investments: 6 | Find email | ||
Dan Devine
Regenerative Medicine Research Fund Advisory Committee Member
|
Regenerative Medicine Research Fund Advisory Committee Member | Total investments: 0 | Find email | |
Daniel Wagner
Sr. Managing Director, Investments
|
Sr. Managing Director, Investments | Total investments: 15 | Find email | |
| See all 14 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| UltraSight aims to revolutionize ultrasound through the power of machine learning to enable more accurate and timely clinical decisions. The UltraSight automated guidance system helps bring the benefits of cardiac imaging to healthcare professionals in new care settings, allowing patients access to ultrasound anywhere. UltraSight won the TCT 2020Innovation Competition which took place during the Transcatheter Cardiovascular Therapeutics world conference. For mor information please visit us at www.ultrasight.com | $24M / Series B / Sep 23, 2026 | ||
| Queen One is creating innovative technology that, in a far more meaningful way than WeChat, texting, or email, links individuals with brands and brands with people. | $25M / Venture - Series Unknown / Aug 19, 2026 | ||
| Queen One is creating innovative technology that, in a far more meaningful way than WeChat, texting, or email, links individuals with brands and brands with people. | $2M / Seed / Aug 10, 2026 | ||
FAST Metals
|
FAST Metals is focused on developing innovative methods for the recovery and production of a range of valuable metals, including iron, aluminum, scandium, titanium, and rare earth elements. | $4.3M / Pre-Seed / Jul 29, 2026 | |
| Look Optic is a retail platform designed to make readers wear comfortable eyewear. The company's platform is based on lightweight glasses with blue light protection and ultra-lightweight matte frames that enable readers and consumers with better-quality glass.Founded in 2016 by Andrew Leary and Jonathan Saven, Look Optic is based in NewYork. | Series B / Jul 07, 2026 | ||
| Adaptive insurance, which begins with parametric insurance, seeks to transform how companies develop financial resilience in the face of weather-related and climate-related events. By combining our cutting-edge coverages, real-time climate data, and AI-driven technology, we think we can support them and show business consumers the benefits ofparametric insurance. | $5M / Seed / Jul 07, 2026 | ||
| Rejuvenate Bio is a biotechnology company that develops novel gene therapies for dogs. The company's therapy provides a solution for the mitral valve disease to stop the progression of heart failure in dogs, thus providing pets with extended overall health and maximal lifespan. It was founded in 2017 and is based in San Diego, CA. | $6M / Venture - Series Unknown / Jun 08, 2026 | ||
| Cypher AI is an AI-powered platform built for scientists that provides intelligent digital infrastructure for life sciences R&D, enabling research teams to create, organize, and share custom AI tools with zero coding required. This platform streamlines scientific workflows by automating data analysis, visualization, protocol generation, andrecording, turning messy lab scripts into shareable web apps. | $2M / Seed / May 27, 2026 | ||
| P2 Science a venture-backed, renewable specialty chemicals company, co-founded by Yale scientists, a chemical industry CEO and Elm Street Ventures, an early-stage venture fund. P2 Science has developed a unique process technology for converting renewable feedstocks—including vegetable oils—into high-value, specialty chemicals. These includeflavor, fragrance and cosmetics ingredients. Many of their products are today available only from petrochemical sources. Among the first products to be produced by P2 are vegetable-derived, cost-effective versions of current petrochemical fragrance ingredients. Major users and formulators of specialty chemicals have a strong interest in substituting renewable for petrochemical ingredients. Patrick Foley, a Yale graduate of the PhD program in Environmental Engineering, is P2′s Chief Scientific Officer. Neil Burns, an executive with 20+ years experience in the specialty chemical industry, is the company’s CEO. P2 has a laboratory in New Haven, CT to support this technology’s development and commercialization, as well as partnerships with major companies at a number of points along the supply chain. | $23M / May 26, 2026 | ||
| Neurosoft Bioelectronics is developing next-generation soft implantable electrodes to interface with the nervous system. Neural implants are medical devices made of electrodes that can record or stimulate the brain, spinal cord, or peripheral nerves to monitor or treat patients suffering from neurological disorders. However, current clinicaldevices are too stiff compared to the soft tissues of the body, which limits benefits for patients. At Neurosoft Bioelectronics, we have developed a new generation of soft and conformable implantable electrodes that seamlessly interface with the nervous tissues and can improve clinical outcomes for patients. | $7.5M / Seed / May 20, 2026 | ||
| See all 309 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Featured in Investor Lists
Recommended lists
FAQ
What does Connecticut Innovations invest in?
Connecticut Innovations invests primarily in Health Care, Biotechnology and Software startups, most often at Seed and Series A stage. Most of the 309 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Connecticut Innovations's check size?
Connecticut Innovations typically joins rounds of $150k–$5.3M at Seed, $1.8M–$25M at Series A and $1.8M–$75M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Connecticut Innovations participates in.
How do I contact Connecticut Innovations?
Public channels for Connecticut Innovations include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Connecticut Innovations?
The team at Connecticut Innovations includes Alison Malloy (Managing Director, Investments), Matthew D. Storeygard (Managing Director, Venture Capital Investments) and Matthew J. McCooe (CEO), among 14 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
